This Article Full Text (PDF) All Versions of this Article: 0897190008322243v1 22/1/104    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wall, G. C. Articles by Cooper, S. A. Search for Related Content Social Bookmarking                         What's this?

Gout and Hyperuricemia: New Guidelines and Treatments

Iowa Methodist Medical Center, Des Moines, College of Pharmacy and Health Sciences, Drake University, Des Moines, Iowa, geoff.wall{at}drake.edu

Sarah A. Cooper

College of Pharmacy and Health Sciences, Drake University, Des Moines, Iowa

Gout is the most common inflammatory arthritis in western countries and the incidence is increasing. Additionally, evidence now exists that cases of severe, refractory gout seem to be increasing. The management of gout and hyperuricemia has remained largely unchanged for decades and includes antiinflammatories used initially for acute attacks and primarily allopurinol to prevent future attacks. Evidence-based guidance for the management of gout and hyperuricemia has been plagued by a lack of randomized, controlled studies and the lack of new medications. Recently evidence-based guidelines by the European League Against Rheumatism were published; one of the first attempts by a major medical body to assess the state of gout and hyperuricemia treatment. Additionally, several new compounds seem poised to be released for hyperuricemia treatment. This review details the important aspects of the gout guidelines relating to pharmacotherapy and critically examines the data surrounding new modalities to decrease serum uric acid.

Key Words: gout • treatment • guidelines

This version was published on February 1, 2009

Journal of Pharmacy Practice, Vol. 22, No. 1, 104-115 (2009)
DOI: 10.1177/0897190008322243


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?